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Key messages
What is already known about this subject?
 ► randomised controlled trials (rcts) are a backbone 
of evidence-based medicine. However, rcts include 
populations with strict inclusion criteria.
 ► in psoriatic arthritis (Psa), a largely heterogeneous 
disease, patients are most often excluded from 
rcts on the basis of low swollen joint count and 
comorbidities.
What does this study add?
 ► Populations who would have been excluded from the 
rcts on biological therapy in Psa still receive similar 
benefits and have similar drug survival.
How might this impact on clinical practice?
 ► treatment outcomes from biological disease-mod-
ifying antirheumatic drug rcts in Psa may be ap-
plied to daily clinical practice to all patients.
AbstrAct
Objectives to determine in a retrospective cohort whether 
patients with psoriatic arthritis (Psa) who would not have 
fulfilled the inclusion criteria for randomised controlled 
trials (rcts) for the tnF inhibitor (tnFi) chosen for their 
treatment (excl) have similar benefits and drug survival as 
those patients who would have (incl).
Methods all patients with rheumatic disorders who are 
treated with biological disease-modifying antirheumatic 
drugs in iceland are registered in iceBiO. On 1 February 
2016, 329 individuals with Psa were registered in iceBiO, 
of whom 231 had data available for their first start of tnFi 
and could be evaluated according to the inclusion criteria 
of the respective rcts. Disease activity was collected at 
baseline using Visual analogue Scale (pain, fatigue and 
global (patient and physician) assessments), swollen joint 
count (SJc) and tender joint count (tJc), Disease activity 
Score 28-joint count c reactive protein (DaS28-crP) 
and Health assessment Questionnaire (HaQ). treatment 
response was measured at 6 and 18 months according 
to american college of rheumatology response criteria, 
DaS28-crP and Disease activity Score in Psoriatic arthritis 
for 28 joints. Drug survival rate was also analysed.
Results the demographics of these two groups were 
similar at baseline, although the incl group had higher 
SJc (5.5 vs 3.8) and subsequently higher DaS28-crP 
(4.6 vs 4.2). While a larger change in disease activity was 
observed in the incl group with respect to HaQ and SJc, 
both groups had similar disease activity at follow-up. Drug 
survival was similar in both groups.
Conclusions Patients with Psa who would not have 
fulfilled the inclusion criteria in rcts reach similar disease 
activity scores at follow-up of 6 and 18 months and have 
similar drug survival as those patients who would have 
been included in rcts.
InTROduCTIOn
Psoriatic arthritis (PsA) is a seronegative 
chronic inflammatory arthritis affecting 
individuals with psoriasis. Psoriasis has a vari-
able prevalence, depending on geographical 
area and the method of study and affects 
around 3%–6% of the population, of whom 
18.5%–20.9% also have PsA, according to 
a recent large meta-analysis.1–4 The global 
prevalence of PsA is 133 per 100 000, and in 
Iceland, the prevalence of PsA is estimated 
to be 139 per 100 000.2 PsA is a heterogenic 
disease, the most common form being an 
oligoarticular or polyarticular pattern of 
peripheral arthritis. However, PsA may present 
with axial involvement, with swelling of entire 
digits, that is, dactylitis, or with enthesitis.5 
PsA often debuts in younger adults and may 
cause severe destruction of joints and signifi-
cant disability. There are effective treatment 
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and the main goals of treatment are to reduce pain and 
stiffness and to preserve joint function and health-related 
quality of life in the long term.6 Most patients require 
therapy with disease-modifying antirheumatic drugs 
(DMARDs), for example, methotrexate, with or without 
intra-articular steroid injections, although up to over 
40% require treatment with biological disease-modifying 
antirheumatic drugs (bDMARDs).7 TNF alpha inhibitors 
are most commonly used, while more recently, specific 
cytokine inhibitors, for example, targeting interleukin 
(IL)-17 or IL-12/23, along with non-biological small 
molecules such as phosphodiesterase 4 (PDE4) and Janus 
kinase (JAK) inhibitors, have become available.6 TNF 
inhibitors (TNFi’s) have dramatically altered the disease 
course and improved the quality of life of patients with 
PsA in recent decades. Treatment with TNFi is costly and 
requires resources for close follow-up for efficacy and 
adverse events; however, it is socioeconomically benefi-
cial to provide treatment with TNFi to individuals with 
active PsA.8 9
Randomised controlled trials (RCTs) are a powerful 
tool to evaluate new therapies in comparison with 
placebo or current best practice as RCTs eliminate physi-
cian and patient biases in the most effective possible way. 
Despite this, it may be unclear whether the results from 
RCTs can be generalised to the group of patients seen 
in daily clinical practice.10 11 When conducting RCTs 
for bDMARDs, patients are recruited using strict entry 
criteria, presumably to ensure the correct diagnosis for 
the tested population and to reduce confounding when 
trying to demonstrate treatment superiority.10 We have 
recently reported that two-thirds of patients requiring 
treatment with TNFi for PsA in Iceland would not have 
been eligible for RCTs performed leading up to the 
approval of the respective pharmaceutical products.12 
The most common reason for exclusion in the study is an 
insufficient number of swollen joints (45%) and various 
comorbidities (16%), which is particularly interesting, 
considering the heterogeneity of PsA discussed earlier. 
The main purpose of that study was to examine eligibility 
for RCTs, and reasons for exclusions were not discussed 
in further detail. Fairly limited data exist on inclusion 
or exclusion rates into RCTs in rheumatology. Aside 
from our previous study, we have not encountered other 
studies examining the eligibility of patients with PsA to 
clinical trials, although more has been published on 
the trial eligibility and treatment efficacy of bDMARDs 
among patients with rheumatoid arthritis.13–16 Inclusion 
criteria vary considerably between bDMARD trials in PsA. 
Some require a minimum of as many as six swollen joints, 
while others require active skin disease and no conven-
tional synthetic disease-modifying antirheumatic drugs 
(csDMARDs) except methotrexate. The studies also have 
strict rules regarding comorbidity and/or corticosteroid 
use. These are all important clinical factors that influence 
treatment decisions in daily clinical practice.17–23
In the present study, we aimed to determine on a 
nationwide basis whether patients with PsA, who would 
not have fulfilled the inclusion criteria for RCTs of the 
chosen TNFi, experience similar treatment benefits and 
have comparable drug survival as those patients who did 
fulfil the same inclusion criteria.
MeTHOds
All patients with rheumatic disorders who are treated 
with bDMARDs in Iceland are registered in ICEBIO, a 
nationwide database. ICEBIO is based on the Danish 
Registry for biological therapies in rheumatology or 
DANBIO and was adapted to Icelandic conditions in 
2007.24 Currently, ICEBIO has comprehensive individual 
patient characteristics, along with long-term disease 
activity scores and information on treatment of >98% of 
all patients with PsA treated with bDMARDs in Iceland. 
When the treating rheumatologist deems the use of TNFi 
is indicated, he applies for a drug licence to the Medicine 
Committee at the University Hospital as these drugs are 
almost fully reimbursed in Iceland. The Committee has 
published treatment guidelines that are very similar to 
those published by EULAR (only published in Icelandic). 
An entry into ICEBIO is also required prior to initiation 
of therapy, and generally, a prior csDMARD treatment 
failure is required.
The present study includes all patients with PsA regis-
tered in ICEBIO who received either adalimumab, 
etanercept, golimumab or infliximab as their first biolog-
ical treatment during the period from January 2000 to 
February 2016. This same group of patients has previously 
been studied with regard to infliximab dosing regimens 
and on the influence of obesity on TNFi therapy.25–27 
In our previous study, this patient population was clas-
sified according to the inclusion criteria of respective 
pharmaceutical RCTs, that is, whether they would have 
been included (incl) or excluded (excl) from the RCT 
performed, leading up to market approval of each respec-
tive biological therapy.12 For example, patients receiving 
golimumab were classified according to inclusion criteria 
to the GO-REVEAL trial. We refer to those publications 
for details about the classification process.12 17–23
Information on disease activity, including patient 
Visual Analogue Scale (VAS) for pain, fatigue and 
global assessment, physician VAS global assessment, 
swollen joint count (SJC) and tender joint count (TJC), 
Disease Activity Score 28-joint count C reactive protein 
(DAS28-CRP) and Health Assessment Questionnaire 
(HAQ) scores were extracted from ICEBIO at baseline 
(last visit before starting TNFi), 6 months (nearest visit 
to 180 days (90–210)) and 18 months (540 days (211–
570)). We also collected standard demographic data at 
the time of start of the TNFi treatment. Times for treat-
ment response evaluation were chosen with respect to 
Icelandic biological drug regulations, which require 
a clinical evaluation of efficacy and registration into 
ICEBIO within 7 months of initiation of bDMARDs and 
then annually for renewal of treatment licence. The large 
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Table 1 Baseline characteristics of the two study groups, 
that is, those who met inclusion criteria for randomised 
controlled trial (incl) and those who did not (excl)
Met inclusion 
criteria
Did not meet 
inclusion criteria
Total, n 74 152
Age (years) 49±13 50±13
Female, n (%) 45 (61%) 80 (53%)
Disease duration 









BMI (n=105) 30±6 30±5
TNFα inhibitor 
type, n (%)
  Infliximab 23 (31%) 95 (63%)
  Etanercept 28 (38%) 23 (15%)
  Golimumab 11 (15%) 17 (11%)
  Adalimumab 9 (12%) 6 (4%)
Data are shown as mean values±SD unless otherwise specified.
BMI, body mass index.
in ICEBIO were more sporadic so long after initiation of 
TNFi therapy.
American College of Rheumatology (ACR) response 
was calculated, and patients achieving improvement by 
20% (ACR20) or higher compared with the baseline visit 
were considered to be responding. We calculated the 
Disease Activity Score in Psoriatic Arthritis for 28 joints 
(DAPSA28) and considered a decrease by one or more 
disease categories to be a response to therapy (cut-off 
values for remission (≤4), low (>4 to ≤14), moderate (>14 
to ≤28) and high (>28) disease activities).28 DAPSA28 is 
the following summation: (SJC+TJC)×1.6+patient global 
(0–10 VAS)+pain (0–10 VAS)+C reactive protein (CRP) 
(mg/dL).29 Additionally, we considered DAS28-CRP with 
a decrease by one or more disease activity categories as 
response, for example, moderate DAS28-CRP score (3.2–
5.2) to low (2.6–3.1). DAS28-CRP and DAPSA28 were 
chosen because of availability; we have 66/68 joint exam-
inations entered into our database in only a minority of 
patients, so calculations would be unreliable. Further-
more, we analysed the drug survival rate over the first 
2 years of treatment.
All data were anonymised before analysis. Statistical 
analysis was performed in R V.3.4.2 (R Project for Statis-
tical Computing, Vienna, Austria) and data manip-
ulation in Microsoft Excel V.1805. χ2 test was used for 
comparison between responders and non-responders, 
and drug survival was demonstrated using a Kaplan-
Meier curve, along with a log-rank test between the 
curves. To account for missing data in the response 
criteria, we employed the LUNDEX method, an integra-
tion of clinical response and adherence to therapy in a 
composite value, the multiplication of the proportion of 
patients adhering to therapy by the proportion fulfilling 
the response criteria.30 The groups were further subdi-
vided by subtypes of TNFi and log-rank tests performed 
between each pair of drug survival curves. Unpaired 
t-tests were used for comparison of disease activity indi-
cators and composite scores.
ResulTs
Patients
On 1 February 2016, 1058 individuals were registered in 
ICEBIO, of whom 329 had been diagnosed with PsA. Of 
these, 274 patients initiated their first-ever treatment with 
a TNFi, of whom 226 could be classified using available 
data according to the inclusion criteria for the RCTs of 
adalimumab, etanercept, golimumab or infliximab. This 
group represents the study population, and within this 
group, 74 patients would have fulfilled the inclusion 
criteria (incl), and 152 patients would not have (excl). 
In the incl group, the most commonly used TNFi was 
etanercept (38%), while the most used TNFi in the excl 
group was infliximab (63%). Details on the TNFi used 
are shown in table 1.
demographic data and disease activity at entry of the study
The two groups were similar at baseline with respect to 
age, sex, disease duration, weight, height, body mass 
index, CRP, patient global VAS and physician global VAS, 
as shown in tables 1 and 2. The incl group had a higher 
mean SJC (5.5±3.3 vs 3.8±3.6, p=0.003), and subsequently, 
they had a higher DAS28-CRP score (4.6±0.8 vs 4.2±0.9, 
p=0.01; table 2). Ankylosing Spondylitis Disease Activity 
Score (ASDAS), Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI) and Bath Ankylosing Spondy-
litis Functional Index (BASFI) scores were available for 
<10% of patients and were not further analysed.
disease activity at 6 and 18 months
No difference was noted in patient-reported outcomes 
and disease activity indicators at either 6 or 18 months in 
any of our indicators (DAPSA28, DAS28-CRP, VAS pain, 
VAS fatigue, VAS global patient, VAS global physician, 
TJC or SJC). The excl group had a higher mean CRP of 
6.1±9.6 at 18 months compared with the incl group mean 
of 3.1±2.5, although there was no difference between the 
groups at baseline or at 6 months. Further results are 
shown in table 2.
Response to therapy
Treatment response is outlined in table 3. No difference 
in response was seen between the two groups with respect 
to VAS scores for pain, fatigue, patient global or physi-
cian global assessment. The incl group had a statistically 
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Table 2 Baseline disease activity indicators with response after initiation of first-line TNFα inhibitors, mean values±SD.
Score At baseline At 6 months At 18 months
Incl Excl Incl Excl Incl Excl
VAS pain 65±17 64±22 30±23 35±27 35±28 35±26
VAS fatigue 68±24 66±24 29±25 40±27 37±28 42±29
VAS global 71±21 66±24 31±23 36±29 37±29 39±27
VAS physician 57±16 53±18 28±18 21±19 25±21 22±17
CRP 11±11 12±20 5.1±6.4 5.2±6.5 3.1±2.5* 6.1±9.6*
HAQ 1.2±0.7 1.0±0.7 0.6±0.6 0.6±0.6 0.7±0.7 0.8±0.7
SJC 5.5±3.3* 3.8±3.6* 1.5±1.8 1.1±2.4 1.5±2.5 1.1±2.1
TJC 6.3±3.8 5.4±4.4 2.0±3.1 2.2±4.4 2.4±3.7 1.8±3.1
DAPSA28 45±18 39±24 18±16 18±15 18±14 18±15
DAS28-CRP 4.6±0.8* 4.2±0.9* 2.8±1.1 2.7±1.1 2.7±1.2 2.7±1.1
*Denotes a p value of <0.05 by unpaired t-test on testing for the statistical difference between incl and excl groups (both columns designated 
*).
CRP, C reactive protein; DAPSA28, Disease Activity Score in Psoriatic Arthritis for 28 joints; DAS28-CRP, Disease Activity Score 28-joint 
count C reactive protein; HAQ, Health Assessment Questionnaire; SJC, swollen joint count; VAS, Visual Analogue Scale.
Table 3 Response to first TNFα inhibitors, mean values±SD unless otherwise indicated
Improvement in clinical parameters 6 months P value 18 months P value
Incl Excl Incl Excl
VAS pain −34±30 −29±28 0.50 −29±31 −25±32 0.60
VAS fatigue −35±33 −24±29 0.19 −34±38 −23±32 0.21
VAS patient global −41±38 −28±30 0.12 −38±43 −27±34 0.26
VAS physician global −34±19 −32±19 0.59 −35±24 −30±27 0.38
HAQ −0.8±0.7 −0.3±0.6 0.008* −0.6±0.7 −0.3±0.6 0.051
SJC −4.3±2.7 −2.2±2.7 0.001* −4.4±3.4 −2.2±3.6 0.007*
TJC −4.2±3.8 −2.8±5.1 0.16 −4.0±4.9 −3.9±4.1 0.89
*Denotes a p value of <0.05 by unpaired t-test.
DAPSA28, Disease Activity Score in Psoriatic Arthritis for 28 joints; HAQ, Health Assessment Questionnaire; SJC, swollen joint count; TJC, 
tender joint count; VAS, Visual Analogue Scale.
−0.3±0.6, p=0.008) at 6 months, but this difference did 
not reach statistical significance at 18 months (−0.6±0.7 
vs -0.3±0.6, p=0.051). The incl group also showed a larger 
change in the SJC at 6 months (−4.3±2.7 vs -2.2±2.7, 
p=0.001), and this remained statistically significant at 
18 months (−4.4±3.4 vs -2.2±3.6, p=0.007). No response 
difference between the groups in TJC was noted.
We had sufficient data to calculate treatment 
responses based on ACR criteria and movement between 
DAS28-CRP and DAPSA28 response groups for 75 
patients in our study group, 26 in the incl group and 49 
in excl group (table 4). There were no statistically signif-
icant differences in response between the groups with 
regard to ACR20 at 6 months (77% vs 60%, p=0.207) or 
18 months (69% vs 59%, p=0.545). There was a numer-
ical but not statistically significant difference in the 
proportion of patients achieving American College of 
Rheumatology response criteria, improvement by 50% 
(ACR50) at 6 months, but by 18 months, this differ-
ence had reached statistical significance (65% vs 34%, 
p=0.034). There were no differences noted between the 
groups in achieving American College of Rheumatology 
response criteria, improvement by 70% (ACR70). There 
were no statistically significant differences in the propor-
tion of patients showing response between the groups as 
measured by DAS28-CRP or DAPSA28 at 6 or 18 months.
Since we had a significant number of patients without 
available response data, we performed an evaluation of 
our data correcting for dropouts using the LUNDEX 
method. This revealed no statistically significant differ-
ences at either 6 or 18 months in any of the composite 
disease activity scores, although the numerical differ-
ence remained in ACR50 at both 6 and 18 months. The 
response rates according to this method for the incl and 
excl groups, respectively, were DAS28-CRP 66% to 64% 
at 6 months and 49% to 45% at 18 months; DAPSA28 
71% to 63% at 6 months and 45% to 45% at 18 months; 
ACR20 66% to 54% at 6 months and 42% to 40% at 18 
months; ACR50 49% to 36% at 6 months and 39% to 25% 
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Figure 1 Drug survival curves of all patients with psoriatic 
arthritis receiving their first biological disease-modifying 
antirheumatic drug, divided by their eligibility for clinical 
trials. Included group in blue, excluded group in red. 
Log-rank test between the curves showed no statistical 
difference, p=0.58.
Table 4 Response to first TNFα inhibitors, percentage achieving response by ACR response criteria or decrease in disease 
activity by one DAS28-CRP or DAPSA28 category, along with availability of response calculations
Improvement in clinical scores
n (%) 6 months P value 18 months P value
Incl Excl Incl Excl
ACR response available 26 52 26 49
ACR20 achieved 20 (77%) 31 (60%) 0.25 18 (69%) 29 (59%) 0.55
ACR50 achieved 15 (58%) 21 (40%) 0.23 17 (65%) 18 (37%) 0.034
ACR70 achieved 7 (27%) 12 (23%) 0.93 13 (50%) 14 (28%) 0.11
DAS28 available 26 51 26 51
Response by DAS28-CRP 20 (77%) 36 (71%) 0.75 21 (81%) 34 (67%) 0.30
DAPSA28 available 23 46 24 49
Response by DAPSA28 19 (83%) 32 (70%) 0.38 18 (75%) 35 (71%) 0.97
ACR20/50/70, American College of Rheumatology response criteria, improvement by 20%/50%/70%; DAPSA28, Disease Activity Score 
in Psoriatic Arthritis for 28 joints; DAS28, Disease Activity Score for 28 joints; DAS28-CRP, Disease Activity Score 28-joint count C reactive 
protein.
and 30% to 19% at 18 months. The group of patients who 
had no response measures available at either time point 
did have a numerically longer disease duration (6.7 to 8.1 
years) and higher joint counts (SJC 4.0 to 4.8, TJC 5.2 to 
6.3; p<0.05).
drug survival
The groups had similar 2-year drug survival (figure 1), 
with 46% of the patients having discontinued therapy 
before the end of the second year in the incl group 
(n=74) and 44% in the excl group (n=152). There were 
no statistically significant differences in drug survival 
noted between the two groups when the four types of 
TNFi (adalimumab, etanercept, golimumab or inflix-
imab) were analysed separately (data not shown).
Reasons for discontinuing therapy were similarly distrib-
uted between the two groups, with 41% of incl and 42% 
of excl discontinuing for lack of drug response. Adverse 
events, including various side effects and infections, were 
the reason for discontinuation in 38% of those discontin-
uing in the incl group and 29% in the excl group.
dIsCussIOn
In the present study, we have demonstrated that patients 
with PsA who would not have fulfilled the inclusion 
criteria for the RCTs performed prior to the approval of 
the TNFi did benefit from treatment with TNFi, achieving 
similar levels of disease activity, largely a similar response 
rate and similar drug survival as those who would have 
fulfilled the inclusion criteria in the same RCTs.
This study addresses a well-known and common problem 
in all fields of medicine. Study populations are included 
in RCTs based on strict entry criteria, and as a result, 
clinical decision-making is often based on evidence from 
trials that do not include the typical patient populations 
present in daily clinical practice.10 Patients with PsA are 
such a heterogenic population that it is urgent to confirm 
that the part of the patient population that would not 
have been eligible for these pharmaceutical trials enjoys 
similar benefits from treatment as those who did. With 
databases for long-term bDMARD therapy follow-up such 
as ICEBIO, it is possible to perform observational studies 
on this important issue. The added information from the 
present study on this population of patients with PsA less 
active than those typically included in trials will also help 
guide future research in this population, which in this 
study comprised two-thirds of the entire population of 
patients with PsA available for analysis.
The strict inclusion criteria of RCTs are likely chosen to 
ensure the correct diagnosis and to reduce confounding 
when trying to demonstrate superiority of the treatment.10 
This approach is common and we are not suggesting 
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importance of being aware of this disparity when making 
clinical decisions based on data from RCTs.
Disease activity measures are comparable to previous 
publications from Nordic countries.31 32 In our study, 
the two groups are similar at baseline except for two 
important factors. First, the incl group has a more severe 
disease at baseline, with higher SJC and subsequently a 
higher DAS28-CRP, reflecting their eligibility for clinical 
trials. Second, the groups differ in choice of TNFi, where 
the excl group receives infliximab in two-thirds of cases 
and the incl group in only a third of cases, with etanercept 
being the most commonly used TNFi. During the study 
period, no patients were treated with certolizumab since 
it is not marketed in Iceland. Furthermore, although 
the SJC and HAQ response effects are larger in the incl 
group, both groups converge at a similar disease activity 
level after 6 and 18 months of treatment. We conclude 
that the different effect size is mostly due to more base-
line disease activity in the incl group.
Drug survival is an indirect marker of treatment efficacy 
and it is similar between the groups. Around 45% of each 
group had discontinued treatment after 2 years, which is 
common in bDMARD treatment trials, and the reasons 
for discontinuation were similarly distributed between 
the two groups.33–35 There was no obvious difference in 
drug survival between different TNFi’s in either group, 
although small group sizes do not allow for a detailed 
analysis.
The strength of this study is that it is a population-wide 
study using a data source that contains information on 
more than 98% of all patients receiving biologics in 
Iceland. Additionally, 84% of patients studied for eligi-
bility in our previous publication could be classified 
according to inclusion and exclusion criteria despite the 
retrospective manner of data collection and the require-
ment of 66/68 joint counts in all the TNFi RCTs. However, 
the patients who could not be classified according to RCT 
criteria had a longer disease duration and overall more 
disease activity at baseline. The study is limited by the size 
of the study population since full data for calculating clin-
ical response are only available in a third of the patients, 
reducing statistical power. Furthermore, only 28 joints 
are included in the assessment in most of the ICEBIO 
data with only a few 66/68 joint counts recorded, there-
fore limiting our analysis to 28 joint counts. ICEBIO data 
do not specify which domain of PsA is being treated, and 
although we extracted disease activity markers for axial 
disease, they were documented in <10% of patients, too 
few to allow for any conclusions to be drawn; the same 
applies for enthesitis and dactylitis. Although no differ-
ence is found based on trial eligibility among these 226 
patients, we were only able to calculate response rates in 
one-third of patients. At some time points, we observed 
numerical differences, where the incl group responded 
more frequently to therapy, but this was not statistically 
significant except in the case of ACR50 response at 
18 months. After correction for missing data with the 
LUNDEX method, this difference was only numerically 
but not statistically significant. Thus, a clinically relevant 
effect may not have reached statistical significance due 
to small sample sizes in our study, or alternatively, this 
could be an artefact related to multiple testing. We there-
fore recommend that our work be repeated in another 
registry of patients on biological treatment with a larger 
sample group to achieve more statistical power and to 
enable further subgroup analysis.
Patients with PsA who would not have fulfilled the inclu-
sion criteria in RCTs have similar disease activity scores at 
follow-up and similar drug survival as those patients who 
would have been included in RCTs. Their treatment effect 
size is smaller on some measures, but both groups arrive 
at a similar absolute disease activity, with the difference 
in effect size being potentially explained by more severe 
disease at baseline in the incl group. Thus, treatment 
outcomes for bDMARD treatment in PsA from RCTs may 
likely be applied to daily clinical practice, irrespective of 
whether patients would have fulfilled RCT criteria or not. 
However, more detailed studies are needed on this issue.
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